Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001890 · ClinicalTrials.gov registry record · Phase 2
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
A Phase 2 study of Atherosclerosis and Cytomegalovirus Infections, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00001890 is a Phase 2 study of Atherosclerosis and Cytomegalovirus Infections that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 80 participants, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001890, a Phase 2 study of Atherosclerosis and Cytomegalovirus Infections, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Hardening of the arteries (atherosclerosis) and heart disease are much more common in men than in women. However, as women grow older, especially after menopause the incidence of atherosclerosis and heart disease increases. These findings suggest that estrogen may be protective and help in preventing heart disease. Studies of large groups of post-menopausal women suggest that hormone replacement therapy (therapy that includes estrogen) reduces the risk of heart disease. Estrogen causes favorable changes in particles that carry cholesterol in the blood stream and improves function of blood vessels. Estrogen may also stimulate the immune system's ability to fight off infections that may lead to or contribute to atherosclerosis. Researchers believe two specific infectious agents (Chlamydia pneumoniae and human cytomegalovirus) may cause damage to the lining of blood vessels resulting in inflammation and the development of atherosclerosis. The purpose of this study is to determine if estrogen treatment can change how the immune system responds to chronic infections, by Chlamydia pneumoniae and human cytomegalovirus, in postmenopausal women.
Conditions Studied
Interventions
- DRUG Estrogen therapy
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 1999-05 |
| Est. Completion | 2001-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001890
The ClinicalTrials.gov registry entry for NCT00001890 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (92% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 1 intervention - of which Estrogen therapy is the first listed.
NCT00001890 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001890 about?
NCT00001890 is a clinical study titled "Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections". Hardening of the arteries (atherosclerosis) and heart disease are much more common in men than in women. However, as women grow older, especially after menopause the incidence of atherosclerosis and heart disease increases. These findings suggest that estrogen may be protective and help in preventin...
What is the current status of trial NCT00001890?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 1999-05. Estimated completion is 2001-03.
What conditions does trial NCT00001890 study?
This clinical trial studies the following conditions: Atherosclerosis, Cytomegalovirus Infections, Pneumonia, Bacterial, Postmenopause, Chlamydia Infections.
What interventions are being tested in trial NCT00001890?
The interventions under investigation include: Estrogen therapy (DRUG).
Who is sponsoring clinical trial NCT00001890?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001890 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Advancing Postmenopausal Preventive Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
COMPLETED · Phase 2
-
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
COMPLETED · Phase 2
-
VEAPS: Vitamin E Atherosclerosis Prevention Study
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.